Revolution Medicines yesterday reported Phase 3 data for daraxonrasib, showing a near doubling of overall survival in patients with pancreatic cancer (PDAC). The results are widely viewed as practice-changing and position KRAS inhibition as a new backbone in PDAC. We comment on the consequences for Alligator.
LÄS MER
